CytomX Therapeutics (CTMX) Competitors $0.61 +0.01 (+2.00%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. INBX, ACIU, DMAC, BTMD, SOPH, NGNE, PLX, RAPT, CTNM, and CKPTShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Inhibrx (INBX), AC Immune (ACIU), DiaMedica Therapeutics (DMAC), biote (BTMD), SOPHiA GENETICS (SOPH), Neurogene (NGNE), Protalix BioTherapeutics (PLX), RAPT Therapeutics (RAPT), Contineum Therapeutics (CTNM), and Checkpoint Therapeutics (CKPT). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Inhibrx AC Immune DiaMedica Therapeutics biote SOPHiA GENETICS Neurogene Protalix BioTherapeutics RAPT Therapeutics Contineum Therapeutics Checkpoint Therapeutics CytomX Therapeutics (NASDAQ:CTMX) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Which has higher valuation and earnings, CTMX or INBX? CytomX Therapeutics has higher revenue and earnings than Inhibrx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$138.10M0.35-$570K$0.381.59Inhibrx$200K1,032.86-$154.96MN/AN/A Do analysts prefer CTMX or INBX? CytomX Therapeutics presently has a consensus price target of $5.02, indicating a potential upside of 728.80%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Inhibrx 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor CTMX or INBX? In the previous week, CytomX Therapeutics had 6 more articles in the media than Inhibrx. MarketBeat recorded 10 mentions for CytomX Therapeutics and 4 mentions for Inhibrx. Inhibrx's average media sentiment score of 1.62 beat CytomX Therapeutics' score of 0.28 indicating that Inhibrx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals and insiders believe in CTMX or INBX? 67.8% of CytomX Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 7.0% of CytomX Therapeutics shares are held by insiders. Comparatively, 22.2% of Inhibrx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in CTMX or INBX? CytomX Therapeutics received 343 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 65.38% of users gave CytomX Therapeutics an outperform vote while only 58.49% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformCytomX TherapeuticsOutperform Votes37465.38% Underperform Votes19834.62% InhibrxOutperform Votes3158.49% Underperform Votes2241.51% Is CTMX or INBX more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Inhibrx's net margin of 0.00%. CytomX Therapeutics' return on equity of -41.47% beat Inhibrx's return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics10.96% -41.47% 8.11% Inhibrx N/A -113.74%-80.56% SummaryCytomX Therapeutics beats Inhibrx on 11 of the 15 factors compared between the two stocks. Remove Ads Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.54M$6.92B$5.64B$8.16BDividend YieldN/A2.73%4.56%4.02%P/E Ratio3.567.2424.5519.12Price / Sales0.35226.41379.5993.71Price / CashN/A65.6738.1634.64Price / Book-0.856.526.984.38Net Income-$570,000.00$142.41M$3.20B$247.23M7 Day Performance-9.00%-2.78%-2.04%-0.20%1 Month Performance-10.25%-4.36%3.32%-3.45%1 Year Performance-72.33%-8.10%11.56%2.41% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.2004 of 5 stars$0.61+2.0%$5.02+728.8%-71.8%$48.54M$138.10M3.56170Short Interest ↑INBXInhibrx1.8863 of 5 stars$14.72+2.6%N/A-59.4%$213.09M$200,000.000.00166Short Interest ↓News CoverageACIUAC Immune2.883 of 5 stars$2.12+1.0%$12.00+466.0%-29.9%$212.87M$27.31M-4.61140Short Interest ↑Positive NewsDMACDiaMedica Therapeutics1.6723 of 5 stars$4.95-0.6%$8.00+61.6%+50.0%$212.14MN/A-8.8420BTMDbiote3.5833 of 5 stars$3.90+1.0%$8.00+105.1%-36.9%$211.91M$197.19M15.00194Positive NewsSOPHSOPHiA GENETICS2.677 of 5 stars$3.12+3.3%$6.80+117.9%-25.2%$208.06M$65.17M-2.86520Short Interest ↓NGNENeurogene1.9741 of 5 stars$13.96-1.8%$60.80+335.5%-67.4%$207.38M$925,000.000.0090Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePLXProtalix BioTherapeutics2.2458 of 5 stars$2.60+4.4%$15.00+476.9%+103.3%$202.89M$53.40M-20.00200High Trading VolumeRAPTRAPT Therapeutics3.9338 of 5 stars$1.53+16.8%$5.29+245.5%-82.7%$201.97M$1.53M-0.5580CTNMContineum Therapeutics2.3758 of 5 stars$7.76+8.2%$24.80+219.6%N/A$200.77M$50M-1.5831CKPTCheckpoint Therapeutics2.3409 of 5 stars$4.05-0.5%$4.33+7.0%+96.1%$197.77M$47,000.00-2.2010Upcoming EarningsShort Interest ↓ Remove Ads Related Companies and Tools Related Companies Inhibrx Competitors AC Immune Competitors DiaMedica Therapeutics Competitors biote Competitors SOPHiA GENETICS Competitors Neurogene Competitors Protalix BioTherapeutics Competitors RAPT Therapeutics Competitors Contineum Therapeutics Competitors Checkpoint Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
